Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
This study will compare four different semaglutide versions and different injection tools. The study aims to show similar levels of semaglutide in the blood using different versions of semaglutide.
- Trial name
- NCT03598621
- Testing
- Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- PIONEER 6 (NCT02692716)
- Testing
- semaglutide
- Where
- 228 sites in United States, Algeria and 19 more
- Volunteers
- 3,183 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers.
- Trial name
- NCT05579249
- Testing
- Semaglutide, Orlistat, Phentermine/Topiramate
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy.
- Trial name
- NCT07732218
- Testing
- Semaglutide (Ozempic®)
- Where
- Pakistan
- Volunteers
- 95 people
- Sponsor
- Rehman Medical Institute - RMI
Diabetes Mellitus, Type 2
Emulation of the SOUL Diabetes Trial in Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT06659718
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 43,650 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine…
- Trial name
- SUSTAIN FORTE (NCT03989232)
- Testing
- Semaglutide
- Where
- 129 sites in United States, Bulgaria and 9 more
- Volunteers
- 961 people
- Sponsor
- Novo Nordisk A/S
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
Healthy Volunteers Type 2 Diabetes
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide.
- Trial name
- NCT04878406
- Testing
- NNC0480-0389, Semaglutide
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT06161844
- Testing
- semaglutide injection (HD1916), Ozempic®
- Where
- China
- Volunteers
- 506 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effect of Renal Impairment on the Pharmacokinetics of NN9535
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
- Trial name
- NCT00833716
- Testing
- semaglutide
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
GLP-1 Concentration
Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1
Determine if consuming a high protein nutrition shake reduces gastrointestinal symptoms associated with semaglutide injections.
- Trial name
- NCT07096739
- Testing
- High protein shake
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kate Farms Inc
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients, Obesity &Amp; Overweight
Coronary Flow Reserve Changes After Semaglutide Treatment
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients.
- Trial name
- NCT07190144
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Ekrem Bilal Karaayvaz
Type 1 Diabetes, Diabetes Mellitus, Type 1
Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
A closed-loop insulin system, also referred to as the "artificial pancreas" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration…
- Trial name
- SEMA-AP (NCT05205928)
- Testing
- Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Endothelial Dysfunction, Diabetes Mellitus, Type 1
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
The aim of study is impact of additional treatment with new antidiabetic drugs (semaglutide or empagliflozine) compared to control group in T1DM patients - impact on endothelial function measured by FMD and FPF, arterial…
- Conditions
- Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells
- Trial name
- ENDIS (NCT05857085)
- Testing
- Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- General and Teaching Hospital Celje
Diabetes Mellitus, Type 2
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes
The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with…
- Trial name
- NCT06120556
- Testing
- GLP-1 receptor agonist
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Type 2 Diabetes Mellitus (T2DM)
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
- Trial name
- T2DM (NCT07163624)
- Testing
- Semaglutide Injection (Ozempic®)
- Where
- China
- Volunteers
- 211 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich